Comparison Overview

Xiros

VS

BD

Xiros

Springfield House, Leeds, West Yorkshire, LS19 7UE, GB
Last Update: 2025-05-06 (UTC)
View Profile
Between 750 and 799
http://www.xiros.co.uk

Xiros develops, manufactures, and markets innovative orthopaedic devices and textile implants under our brand Xiros (previously Xiros Surgical and Neoligaments) and provides extensive expertise in research, development, design, manufacture, and marketing to others in the medical field. Working in collaboration with healthcare professionals, medical device companies and academic institutions, we provide various routes to market for inventions in the orthopaedic and sports medicine fields. First winning the Queen’s Award for Enterprise in 2008, Xiros was delighted to achieve this prestigious accolade for a second time in 2016. We are proud to have held the esteemed Investors in People Standard since July 2000 and achieved Investors in People Gold Standard Accreditation in March 2016: an accomplishment which underlines the people-oriented values upon which our company is built. Xiros products and their indications are subject to regional variations. To confirm availability in your region/country please contact [email protected]

NAICS: 3391
NAICS Definition: Medical Equipment and Supplies Manufacturing
Employees: 57
Subsidiaries: 0
12-month incidents
0
Known data breaches
0
Attack type number
0
View Profile

BD

1 Becton Drive, Franklin Lakes, New Jersey, 07417, US
Last Update: 2025-03-04 (UTC)
Between 800 and 849
http://www.bd.com

BD is one of the largest global medical technology companies in the world and is advancing the world of health™ by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its more than 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com. See community guidelines here: https://tinyurl.com/yunjmzkx.

NAICS: 3391
NAICS Definition: Medical Equipment and Supplies Manufacturing
Employees: 43,786
Subsidiaries: 6
12-month incidents
0
Known data breaches
0
Attack type number
0

Compliance Badges Comparison

Security & Compliance Standards Overview

https://images.rankiteo.com/companyimages/xiros.jpeg
Xiros
—
ISO 27001
ISO 27001 certification not verified
Not verified
—
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
—
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
—
GDPR
GDPR certification not verified
Not verified
—
PCI DSS
PCI DSS certification not verified
Not verified
—
HIPAA
HIPAA certification not verified
Not verified
https://images.rankiteo.com/companyimages/bd1.jpeg
BD
—
ISO 27001
ISO 27001 certification not verified
Not verified
—
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
—
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
—
GDPR
GDPR certification not verified
Not verified
—
PCI DSS
PCI DSS certification not verified
Not verified
—
HIPAA
HIPAA certification not verified
Not verified
Compliance Summary
Xiros
100%
Compliance Rate
0/4 Standards Verified
BD
0%
Compliance Rate
0/4 Standards Verified

Benchmark & Cyber Underwriting Signals

Incidents vs Medical Equipment Manufacturing Industry Average (This Year)

No incidents recorded for Xiros in 2025.

Incidents vs Medical Equipment Manufacturing Industry Average (This Year)

No incidents recorded for BD in 2025.

Incident History — Xiros (X = Date, Y = Severity)

Xiros cyber incidents detection timeline including parent company and subsidiaries

Incident History — BD (X = Date, Y = Severity)

BD cyber incidents detection timeline including parent company and subsidiaries

Notable Incidents

Last 3 Security & Risk Events by Company

https://images.rankiteo.com/companyimages/xiros.jpeg
Xiros
Incidents

No Incident

https://images.rankiteo.com/companyimages/bd1.jpeg
BD
Incidents

No Incident

FAQ

BD company demonstrates a stronger AI Cybersecurity Score compared to Xiros company, reflecting its advanced cybersecurity posture governance and monitoring frameworks.

Historically, BD company has disclosed a higher number of cyber incidents compared to Xiros company.

In the current year, BD company and Xiros company have not reported any cyber incidents.

Neither BD company nor Xiros company has reported experiencing a ransomware attack publicly.

Neither BD company nor Xiros company has reported experiencing a data breach publicly.

Neither BD company nor Xiros company has reported experiencing targeted cyberattacks publicly.

Neither Xiros company nor BD company has reported experiencing or disclosing vulnerabilities publicly.

Neither Xiros nor BD holds any compliance certifications.

Neither company holds any compliance certifications.

BD company has more subsidiaries worldwide compared to Xiros company.

BD company employs more people globally than Xiros company, reflecting its scale as a Medical Equipment Manufacturing.

Neither Xiros nor BD holds SOC 2 Type 1 certification.

Neither Xiros nor BD holds SOC 2 Type 2 certification.

Neither Xiros nor BD holds ISO 27001 certification.

Neither Xiros nor BD holds PCI DSS certification.

Neither Xiros nor BD holds HIPAA certification.

Neither Xiros nor BD holds GDPR certification.

Latest Global CVEs (Not Company-Specific)

Description

The Bold Page Builder plugin for WordPress is vulnerable to Stored Cross-Site Scripting via the ‘percentage’ parameter in all versions up to, and including, 5.4.5 due to insufficient input sanitization and output escaping. This makes it possible for authenticated attackers, with Contributor-level access and above, to inject arbitrary web scripts in pages that will execute whenever a user accesses an injected page.

Published
Date
2025-10-23
Updated
Date
2025-10-23
Risk Information
cvss3
Base: 6.4
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:C/C:L/I:L/A:N
References
Description

The ComboServlet in Liferay Portal 7.4.0 through 7.4.3.111, and older unsupported versions, and Liferay DXP 2023.Q4.0 through 2023.Q4.2, 2023.Q3.1 through 2023.Q3.5, 7.4 GA through update 92, 7.3 GA through update 35, and older unsupported versions does not limit the number or size of the files it will combine, which allows remote attackers to create very large responses that lead to a denial of service attack via the URL query string.

Published
Date
2025-10-23
Updated
Date
2025-10-23
Risk Information
cvss4
Base: 6.9
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:N/VI:N/VA:L/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
References
Description

A relative path traversal vulnerability was discovered in Productivity Suite software version 4.4.1.19. The vulnerability allows an unauthenticated remote attacker to interact with the ProductivityService PLC simulator and delete arbitrary directories on the target machine.

Published
Date
2025-10-23
Updated
Date
2025-10-23
Risk Information
cvss3
Base: 4.0
Severity: HIGH
CVSS:3.1/AV:N/AC:H/PR:N/UI:N/S:C/C:N/I:L/A:N
cvss4
Base: 6.3
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:P/PR:N/UI:N/VC:N/VI:L/VA:N/SC:N/SI:L/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
References
Description

A relative path traversal vulnerability was discovered in Productivity Suite software version 4.4.1.19. The vulnerability allows an unauthenticated remote attacker to interact with the ProductivityService PLC simulator and create arbitrary directories on the target machine.

Published
Date
2025-10-23
Updated
Date
2025-10-23
Risk Information
cvss3
Base: 4.0
Severity: HIGH
CVSS:3.1/AV:N/AC:H/PR:N/UI:N/S:C/C:N/I:L/A:N
cvss4
Base: 6.3
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:P/PR:N/UI:N/VC:N/VI:L/VA:N/SC:N/SI:L/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
References
Description

A relative path traversal vulnerability was discovered in Productivity Suite software version 4.4.1.19. The vulnerability allows an unauthenticated remote attacker to interact with the ProductivityService PLC simulator and delete arbitrary files on the target machine.

Published
Date
2025-10-23
Updated
Date
2025-10-23
Risk Information
cvss3
Base: 7.5
Severity: HIGH
CVSS:3.1/AV:N/AC:H/PR:N/UI:N/S:C/C:N/I:L/A:H
cvss4
Base: 8.3
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:P/PR:N/UI:N/VC:N/VI:L/VA:H/SC:N/SI:L/SA:L/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
References